<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on Νοέμβριος 19, 2026 at 10:41 μμ by All in One SEO v5.0.5.1 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://ogkologos.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>Ogkologos.com</title>
		<link><![CDATA[https://ogkologos.com]]></link>
		<description><![CDATA[Ogkologos.com]]></description>
		<lastBuildDate><![CDATA[Wed, 18 Nov 2026 07:45:00 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://ogkologos.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://ogkologos.com/ai-for-early-cancer-detection-where-are-we-now/]]></guid>
			<link><![CDATA[https://ogkologos.com/ai-for-early-cancer-detection-where-are-we-now/]]></link>
			<title>AI for early cancer detection: where are we now?</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 07:45:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/could-virtual-reality-become-a-reality-in-cancer-supportive-care/]]></guid>
			<link><![CDATA[https://ogkologos.com/could-virtual-reality-become-a-reality-in-cancer-supportive-care/]]></link>
			<title>Could virtual reality become a reality in cancer supportive care?</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 12:30:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/ccdi-activities-enhance-ncis-childhood-and-aya-cancer-research/]]></guid>
			<link><![CDATA[https://ogkologos.com/ccdi-activities-enhance-ncis-childhood-and-aya-cancer-research/]]></link>
			<title>CCDI Activities Enhance NCI’s Childhood and AYA Cancer Research</title>
			<pubDate><![CDATA[Tue, 17 Nov 2026 07:56:42 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/κέντρα-καρκίνου-ογκολόγοι/]]></guid>
			<link><![CDATA[https://ogkologos.com/κέντρα-καρκίνου-ογκολόγοι/]]></link>
			<title>ΚΕΝΤΡΑ ΚΑΡΚΙΝΟΥ &#8211; ΟΓΚΟΛΟΓΟΙ</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 10:53:10 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/ema-recommends-granting-a-marketing-authorisation-for-daraxonrasib/]]></guid>
			<link><![CDATA[https://ogkologos.com/ema-recommends-granting-a-marketing-authorisation-for-daraxonrasib/]]></link>
			<title>EMA recommends granting a marketing authorisation for daraxonrasib</title>
			<pubDate><![CDATA[Thu, 12 Nov 2026 15:06:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/τύποι-καρκίνου/]]></guid>
			<link><![CDATA[https://ogkologos.com/τύποι-καρκίνου/]]></link>
			<title>Τύποι καρκίνου</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 08:48:53 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/ερωτήσεις-μετά-τη-διάγνωση/]]></guid>
			<link><![CDATA[https://ogkologos.com/ερωτήσεις-μετά-τη-διάγνωση/]]></link>
			<title>Ερωτήσεις μετά τη διάγνωση</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 08:09:54 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/υποστήριξη/]]></guid>
			<link><![CDATA[https://ogkologos.com/υποστήριξη/]]></link>
			<title>Υποστήριξη</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 08:06:16 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/esmo-and-asco-publish-joint-consensus-statement-on-streamlining-clinical-research/]]></guid>
			<link><![CDATA[https://ogkologos.com/esmo-and-asco-publish-joint-consensus-statement-on-streamlining-clinical-research/]]></link>
			<title>ESMO and ASCO publish joint consensus statement on streamlining clinical research </title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 07:34:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/how-to-select-adjuvant-endocrine-therapy-for-postmenopausal-women-with-hr-positive-early-breast-cancer/]]></guid>
			<link><![CDATA[https://ogkologos.com/how-to-select-adjuvant-endocrine-therapy-for-postmenopausal-women-with-hr-positive-early-breast-cancer/]]></link>
			<title>How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer?</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 07:34:16 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/]]></guid>
			<link><![CDATA[https://ogkologos.com/]]></link>
			<title>ΑΡΧΙΚΗ</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 07:29:42 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/can-ctdna-guide-treatment-intensification-in-egfr-mutated-non-small-cell-lung-cancer/]]></guid>
			<link><![CDATA[https://ogkologos.com/can-ctdna-guide-treatment-intensification-in-egfr-mutated-non-small-cell-lung-cancer/]]></link>
			<title>Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer?</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 07:17:05 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/θεραπείες/στοχευμένη-θεραπεία/]]></guid>
			<link><![CDATA[https://ogkologos.com/θεραπείες/στοχευμένη-θεραπεία/]]></link>
			<title>Στοχευμένη θεραπεία</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 07:15:20 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/θεραπείες/χειρουργική-θεραπεία/]]></guid>
			<link><![CDATA[https://ogkologos.com/θεραπείες/χειρουργική-θεραπεία/]]></link>
			<title>Χειρουργική θεραπεία</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 07:15:19 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/θεραπείες/ορμονοθεραπεία/]]></guid>
			<link><![CDATA[https://ogkologos.com/θεραπείες/ορμονοθεραπεία/]]></link>
			<title>Ορμονοθεραπεία</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 07:15:19 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/ακτινοθεραπεία/]]></guid>
			<link><![CDATA[https://ogkologos.com/ακτινοθεραπεία/]]></link>
			<title>Ακτινοθεραπεία</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 07:13:41 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/θεραπείες/ανοσοθεραπεία/]]></guid>
			<link><![CDATA[https://ogkologos.com/θεραπείες/ανοσοθεραπεία/]]></link>
			<title>Ανοσοθεραπεία</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 07:13:41 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/θεραπείες/χημειοθεραπεία/]]></guid>
			<link><![CDATA[https://ogkologos.com/θεραπείες/χημειοθεραπεία/]]></link>
			<title>Χημειοθεραπεία</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 07:13:41 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/τύποι-καρκίνου/καρκίνος-μαστού/]]></guid>
			<link><![CDATA[https://ogkologos.com/τύποι-καρκίνου/καρκίνος-μαστού/]]></link>
			<title>Καρκίνος μαστού</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 07:13:15 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/τύποι-καρκίνου/καρκίνος-παχέος-εντέρου-και-ορθού/]]></guid>
			<link><![CDATA[https://ogkologos.com/τύποι-καρκίνου/καρκίνος-παχέος-εντέρου-και-ορθού/]]></link>
			<title>Καρκίνος παχέος εντέρου και ορθού</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 07:13:15 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/τύποι-καρκίνου/καρκίνος-πνεύμονα/]]></guid>
			<link><![CDATA[https://ogkologos.com/τύποι-καρκίνου/καρκίνος-πνεύμονα/]]></link>
			<title>Καρκίνος πνεύμονα</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 07:10:26 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/πρώτο-ογκολογικό-ραντεβού/]]></guid>
			<link><![CDATA[https://ogkologos.com/πρώτο-ογκολογικό-ραντεβού/]]></link>
			<title>Πρώτο ογκολογικό ραντεβού</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 07:08:07 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/πρόληψη-και-προσυμπτωματικός-έλεγχο/]]></guid>
			<link><![CDATA[https://ogkologos.com/πρόληψη-και-προσυμπτωματικός-έλεγχο/]]></link>
			<title>Πρόληψη και προσυμπτωματικός έλεγχος</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 07:04:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/θεραπείες/]]></guid>
			<link><![CDATA[https://ogkologos.com/θεραπείες/]]></link>
			<title>Θεραπείες</title>
			<pubDate><![CDATA[Tue, 10 Nov 2026 13:36:05 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/karkinos/ti-einai/]]></guid>
			<link><![CDATA[https://ogkologos.com/karkinos/ti-einai/]]></link>
			<title>Τι είναι ο καρκίνος</title>
			<pubDate><![CDATA[Tue, 10 Nov 2026 13:28:08 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/νέα/]]></guid>
			<link><![CDATA[https://ogkologos.com/νέα/]]></link>
			<title>Νέα</title>
			<pubDate><![CDATA[Tue, 10 Nov 2026 11:40:59 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/730-2/]]></guid>
			<link><![CDATA[https://ogkologos.com/730-2/]]></link>
			<title>ΜΥΘΟΙ ΚΑΙ ΑΛΗΘΕΙΕΣ</title>
			<pubDate><![CDATA[Tue, 10 Nov 2026 11:39:05 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/karkinos/pws-anaptisetai123/]]></guid>
			<link><![CDATA[https://ogkologos.com/karkinos/pws-anaptisetai123/]]></link>
			<title>Πώς αναπτύσσεται ο καρκίνος</title>
			<pubDate><![CDATA[Mon, 09 Nov 2026 11:50:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/delivering-palliative-care-by-telehealth-meets-the-needs-of-people-with-cancer/]]></guid>
			<link><![CDATA[https://ogkologos.com/delivering-palliative-care-by-telehealth-meets-the-needs-of-people-with-cancer/]]></link>
			<title>Delivering Palliative Care by Telehealth Meets the Needs of People with Cancer</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 07:14:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/extended-lymphadenectomy-does-not-improve-dfs-or-os-among-patients-with-localised-muscle-invasive-bladder-cancer/]]></guid>
			<link><![CDATA[https://ogkologos.com/extended-lymphadenectomy-does-not-improve-dfs-or-os-among-patients-with-localised-muscle-invasive-bladder-cancer/]]></link>
			<title>Extended Lymphadenectomy Does Not Improve DFS or OS Among Patients with Localised Muscle Invasive Bladder Cancer</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 07:14:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/program-connects-adolescents-and-young-adults-to-quality-cancer-care/]]></guid>
			<link><![CDATA[https://ogkologos.com/program-connects-adolescents-and-young-adults-to-quality-cancer-care/]]></link>
			<title>Program Connects Adolescents and Young Adults to Quality Cancer Care</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 07:14:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/ema-recommends-extension-of-indications-for-ribociclib-to-include-use-in-patients-with-early-breast-cancer/]]></guid>
			<link><![CDATA[https://ogkologos.com/ema-recommends-extension-of-indications-for-ribociclib-to-include-use-in-patients-with-early-breast-cancer/]]></link>
			<title>EMA Recommends Extension of Indications for Ribociclib to Include Use in Patients with Early Breast Cancer</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 07:14:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/fda-grants-traditional-approval-for-selpercatinib-for-medullary-thyroid-cancer-with-a-ret-mutation/]]></guid>
			<link><![CDATA[https://ogkologos.com/fda-grants-traditional-approval-for-selpercatinib-for-medullary-thyroid-cancer-with-a-ret-mutation/]]></link>
			<title>FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with a RET Mutation</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 07:14:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/bladder-cancer-trial-finds-extended-lymph-node-surgery-doesnt-improve-survival/]]></guid>
			<link><![CDATA[https://ogkologos.com/bladder-cancer-trial-finds-extended-lymph-node-surgery-doesnt-improve-survival/]]></link>
			<title>Bladder Cancer Trial Finds Extended Lymph Node Surgery Doesn’t Improve Survival</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 07:14:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/five-fraction-sbrt-noninferior-to-moderately-fractionated-image-guided-radiotherapy-for-patients-with-low-to-intermediate-risk-localised-prostate-cancer/]]></guid>
			<link><![CDATA[https://ogkologos.com/five-fraction-sbrt-noninferior-to-moderately-fractionated-image-guided-radiotherapy-for-patients-with-low-to-intermediate-risk-localised-prostate-cancer/]]></link>
			<title>Five Fraction SBRT Noninferior to Moderately Fractionated Image-Guided Radiotherapy for Patients with Low to Intermediate Risk Localised Prostate Cancer</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 07:14:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/neoadjuvant-pembrolizumab-plus-chemotherapy-followed-by-adjuvant-pembrolizumab-prolongs-os-among-patients-with-early-stage-tnbc/]]></guid>
			<link><![CDATA[https://ogkologos.com/neoadjuvant-pembrolizumab-plus-chemotherapy-followed-by-adjuvant-pembrolizumab-prolongs-os-among-patients-with-early-stage-tnbc/]]></link>
			<title>Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among Patients with Early-Stage TNBC</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 07:14:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/fda-approves-amivantamab-vmjw-with-carboplatin-and-pemetrexed-for-non-small-cell-lung-cancer-with-egfr-exon-19-deletions-or-l858r-mutations/]]></guid>
			<link><![CDATA[https://ogkologos.com/fda-approves-amivantamab-vmjw-with-carboplatin-and-pemetrexed-for-non-small-cell-lung-cancer-with-egfr-exon-19-deletions-or-l858r-mutations/]]></link>
			<title>FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for Non-Small Cell Lung Cancer with EGFR Exon 19 Deletions or L858R Mutations</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 07:14:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/fda-approves-ribociclib-with-an-aromatase-inhibitor-and-ribociclib-and-letrozole-co-pack-for-early-high-risk-breast-cancer/]]></guid>
			<link><![CDATA[https://ogkologos.com/fda-approves-ribociclib-with-an-aromatase-inhibitor-and-ribociclib-and-letrozole-co-pack-for-early-high-risk-breast-cancer/]]></link>
			<title>FDA Approves Ribociclib with an Aromatase Inhibitor and Ribociclib and Letrozole Co-pack for Early High-Risk Breast Cancer</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 07:14:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/greater-os-benefit-among-patients-with-advanced-cancer-treated-with-matched-targeted-therapy-based-on-biomarkers-identified-by-ctdna-genotyping/]]></guid>
			<link><![CDATA[https://ogkologos.com/greater-os-benefit-among-patients-with-advanced-cancer-treated-with-matched-targeted-therapy-based-on-biomarkers-identified-by-ctdna-genotyping/]]></link>
			<title>Greater OS Benefit Among Patients with Advanced Cancer Treated with Matched Targeted Therapy Based on Biomarkers Identified by ctDNA Genotyping</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 07:14:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/ema-recommends-granting-a-marketing-authorisation-for-catumaxomab/]]></guid>
			<link><![CDATA[https://ogkologos.com/ema-recommends-granting-a-marketing-authorisation-for-catumaxomab/]]></link>
			<title>EMA Recommends Granting a Marketing Authorisation for Catumaxomab</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 07:14:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/cabozantinib-improves-pfs-in-patients-with-previously-treated-progressive-advanced-extrapancreatic-or-pancreatic-neuroendocrine-tumours/]]></guid>
			<link><![CDATA[https://ogkologos.com/cabozantinib-improves-pfs-in-patients-with-previously-treated-progressive-advanced-extrapancreatic-or-pancreatic-neuroendocrine-tumours/]]></link>
			<title>Cabozantinib Improves PFS in Patients with Previously Treated, Progressive Advanced Extrapancreatic or Pancreatic Neuroendocrine Tumours</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 07:14:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/women-diagnosed-with-early-breast-cancer-since-2000-have-about-a-fifth-lower-rate-of-distant-recurrence-than-those-diagnosed-in-the-1990s/]]></guid>
			<link><![CDATA[https://ogkologos.com/women-diagnosed-with-early-breast-cancer-since-2000-have-about-a-fifth-lower-rate-of-distant-recurrence-than-those-diagnosed-in-the-1990s/]]></link>
			<title>Women Diagnosed with Early Breast Cancer Since 2000 Have About a Fifth Lower Rate of Distant Recurrence Than Those Diagnosed in the 1990s</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 07:14:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/fda-approves-zolbetuximab-clzb-with-chemotherapy-for-gastric-or-gastro-oesophageal-junction-adenocarcinoma/]]></guid>
			<link><![CDATA[https://ogkologos.com/fda-approves-zolbetuximab-clzb-with-chemotherapy-for-gastric-or-gastro-oesophageal-junction-adenocarcinoma/]]></link>
			<title>FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 07:14:16 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/nivolumab-appears-to-boost-cure-rate-in-advanced-hodgkin-lymphoma/]]></guid>
			<link><![CDATA[https://ogkologos.com/nivolumab-appears-to-boost-cure-rate-in-advanced-hodgkin-lymphoma/]]></link>
			<title>Nivolumab Appears to Boost Cure Rate in Advanced Hodgkin Lymphoma</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 07:14:16 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/idfs-benefit-with-ribociclib-plus-nonsteroidal-aromatase-inhibitor-in-patients-with-hr-positive-her2-negative-early-breast-cancer/]]></guid>
			<link><![CDATA[https://ogkologos.com/idfs-benefit-with-ribociclib-plus-nonsteroidal-aromatase-inhibitor-in-patients-with-hr-positive-her2-negative-early-breast-cancer/]]></link>
			<title>iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with HR-positive, HER2-negative Early Breast Cancer</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 07:14:16 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/adding-cadonilimab-to-first-line-standard-chemotherapy-significantly-improves-pfs-and-os-in-patients-with-persistent-recurrent-or-metastatic-cervical-cancer/]]></guid>
			<link><![CDATA[https://ogkologos.com/adding-cadonilimab-to-first-line-standard-chemotherapy-significantly-improves-pfs-and-os-in-patients-with-persistent-recurrent-or-metastatic-cervical-cancer/]]></link>
			<title>Adding Cadonilimab to First-Line Standard Chemotherapy Significantly Improves PFS and OS in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 07:14:16 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/how-do-black-people-with-cancer-view-clinical-research/]]></guid>
			<link><![CDATA[https://ogkologos.com/how-do-black-people-with-cancer-view-clinical-research/]]></link>
			<title>How Do Black People with Cancer View Clinical Research?</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 07:14:16 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/perioperative-durvalumab-plus-neoadjuvant-chemotherapy-improves-efs-and-os-in-cisplatin-eligible-patients-with-muscle-invasive-bladder-cancer/]]></guid>
			<link><![CDATA[https://ogkologos.com/perioperative-durvalumab-plus-neoadjuvant-chemotherapy-improves-efs-and-os-in-cisplatin-eligible-patients-with-muscle-invasive-bladder-cancer/]]></link>
			<title>Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients with Muscle Invasive Bladder Cancer</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 07:14:16 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/ema-recommends-extension-of-indications-for-tislelizumab-to-first-line-treatment-of-gastric-or-gej-adenocarcinoma-and-oesophageal-squamous-cell-carcinoma/]]></guid>
			<link><![CDATA[https://ogkologos.com/ema-recommends-extension-of-indications-for-tislelizumab-to-first-line-treatment-of-gastric-or-gej-adenocarcinoma-and-oesophageal-squamous-cell-carcinoma/]]></link>
			<title>EMA Recommends Extension of Indications for Tislelizumab to First-Line Treatment of Gastric or GEJ Adenocarcinoma and Oesophageal Squamous Cell Carcinoma</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 07:14:16 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ogkologos.com/fda-approves-inavolisib-with-palbociclib-and-fulvestrant-for-endocrine-resistant-pik3ca-mutated-hr-positive-her2-negative-advanced-breast-cancer/]]></guid>
			<link><![CDATA[https://ogkologos.com/fda-approves-inavolisib-with-palbociclib-and-fulvestrant-for-endocrine-resistant-pik3ca-mutated-hr-positive-her2-negative-advanced-breast-cancer/]]></link>
			<title>FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive, HER2-negative Advanced Breast Cancer</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 07:14:16 +0000]]></pubDate>
		</item>
				</channel>
</rss>
